 AIM ImmunoTech Inc NYSEAMERICAN:AIM FRA:HXB2 reports that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential treatment option for cancer patients infected with SARS-CoV-2. In a statement, the company said the studys authors stated that Ampligen has the potential to reduce the severity of the deadly respiratory disease COVID-19, which has so far caused more than 3.7 million deaths globally. 